Merck and Novartis joined a host of philanthropic and state-backed entities for a $300m fund that will invest in medical technologies for conditions often ignored by venture capital.
US-based life sciences investment firm Adjuvant Capital raised $300m for an oversubscribed fund yesterday from investors including pharmaceutical firms Merck and Novartis. Limited partners also include Bill and Melinda Gates Foundation, Anthos Fund and Asset Management, Beacon Pointe Advisors, CDC Group, Children’s Investment Fund Foundation, Dalio Philanthropies, Doris Duke Charitable Foundation and Elma Investments. Ford…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.